According to a BioSpace report, Basilea Pharmaceutica have announced that it will be filing an application for marketing authorisation of ceftobiprole in the EU for the treatment of severe pneumonia in the hospital setting in the second half of 2012.  Please see the link below for further information.

[Editor’s note: A previous marketing authorisation application for this drug for a different indication – the treatment of complicated skin and soft tissue infections – was refused by the CHMP – please see the link below].